Home/Pipeline/Telitacicept (RC18)

Telitacicept (RC18)

Systemic Lupus Erythematosus (SLE)

ApprovedMarketed

Key Facts

Indication

Systemic Lupus Erythematosus (SLE)

Phase

Approved

Status

Marketed

Company

RemeGen, RemeGen, RemeGen

About RemeGen

A leading Chinese biotech developing and commercializing innovative biologics and ADCs for autoimmune diseases, oncology, and ophthalmology.

View full company profile

About RemeGen

A leading Chinese biotech developing and commercializing innovative biologics and ADCs for autoimmune diseases, oncology, and ophthalmology.

View full company profile

About RemeGen

A leading Chinese biotech developing and commercializing innovative biologics and ADCs for autoimmune diseases, oncology, and ophthalmology.

View full company profile

Therapeutic Areas

Oncology Immunology Ophthalmology

Other Systemic Lupus Erythematosus (SLE) Drugs

Drug	Company	Phase	Status
hCDR1 (Edratide)	XTL Biopharmaceuticals	Phase 2	Completed
Nipocalimab	Johnson and Johnson Innovative Medicine	Phase 3	Active (Fast Track Designation)
EYD-001 (Takinib analog)	EydisBio	Preclinical	Potential indication
IFNα Kinoid (IFN-K)	Neovacs	Phase IIb	Inactive / On Hold
Brepocitinib (PF-06700841)	Priovant Therapeutics	Phase 3	Active
aiSLE® DX Flare Risk Index	Progentec Diagnostics	Commercial	Active
aiSLE® DX Disease Activity Index	Progentec Diagnostics	Commercial	Active
OASIS Study (Digital Biomarkers)	Progentec Diagnostics	Clinical Study	Active
RSLV-132	Resolve Therapeutics	Phase 2	Completed
Mini-CAR for SLE	Caravan Biologix	Pre-clinical	Active
Internal Program	BenevolentAI	Preclinical	Active
Cenerimod	Ono Pharmaceutical	Phase 3	Active